Compare Docusign Inc (DOCU) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs Johnson & Johnson — how do they compare? Docusign Inc trades at $70.15 (market cap $13.35B), while Johnson & Johnson trades at $261.04 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 46.3× Docusign Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and Johnson & Johnson for 129 Days on average.
| DOCU | JNJ | |
|---|---|---|
Market Cap | $13.35B | $618.09B |
Volume | 3,158,858 | 6,050,983 |
Sector | Technology | Health |
52-Week High | $73.14 | $278.43 |
52-Week Low | $41.75 | $186.00 |
Typical Hold Time | 71 Days | 129 Days |
Enterprise Value | $12.76B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $70.08, up 1.71% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.98 billion in 2025, with net income surging to $1.07 billion, though cash flow turned negative. Recent news highlights AI integration in contract processing and leadership in workflow software.
Outlook remains positive with continued earnings momentum and AI-driven growth, but risks include insider selling and competitive pressures. The stock offers growth potential but requires monitoring of cash flow trends and market saturation in e-signature adoption.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
